Investing Profile

Ken Belotsky

VC
Founding Partner at Negev Capital. Leading VC in psychedelic drug development
negevcap.comTel Aviv, Israel
Photo of Ken Belotsky, Managing Partner at Negev Capital

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Negev Capital Managing Partner
$500K - $3.0M
$1M
6
CompanyStageDateRound SizeTotal Raised
Gilgamesh Pharmaceuticals
series BMay 2022$1
$68M
Co-investors: Eric Brook (B Capital Group), Kunal Sethi (Prithvi Ventures), Stephen Hays (What If Ventures), Amy Kruse (Prime Movers Lab), Martin Tobias (Incisive Ventures), Lucas Vaz (Ravelin Capital), Rand Hindi
Mindstate Design Labs
Seed RoundFeb 2022$12M
$24M
Co-investors: Fred Ehrsam (Paradigm), Eric Brook (B Capital Group), Kunal Sethi (Prithvi Ventures), Naval Ravikant (The Hit Forge), Rand Hindi
Delix Therapeutics
Series ASep 2021$70M
$70M
Co-investors: Andrew Levin (RA Capital), Matias Serebrinsky (PsyMed Ventures), Vasudev Bailey (Artis Ventures (AV))
Beckley Psytech
Series BAug 2021£58M
$80M
£58M
Co-investors: Eric Brook (B Capital Group), Kunal Sethi (Prithvi Ventures), Matias Serebrinsky (PsyMed Ventures), Stephen Hays (What If Ventures), Amy Kruse (Prime Movers Lab)
ATAI Life Sciences
Series BMar 2019$43M
$690M
Co-investors: Peter Thiel (Founders Fund), Stephen Hays (What If Ventures), Matias Serebrinsky (PsyMed Ventures), Maryanna Saenko (Future Ventures), Victor Douce (Brkfst Club), Jason Camm (Thiel Capital), Martin Alexander Gershon (Endeavor Venture Funds), Christian Angermayer (Presight Capital), Steve Jurvetson (Future Ventures), Nico Wittenborn (Adjacent), Miyuki Matsumoto (Aglae Ventures), Janice Bourque (Hercules Capital), Akshay Sriprasad
Small Pharma
Seed RoundApr 2017£830K
$1M
£830K
Co-investors: David Ebsworth, Peter Keen